Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Dementia and Cognitive Improvement

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments

Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).

1 finding from 1 review